Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Therapy with Docetaxel and Abiraterone Acetate in Castration-Resistant Prostate Cancer: Real-World Survival Analysis
TCTR20260530001Active, not recruiting
- Sponsor
- N/A
- Start
- Nov 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of docetaxel and abiraterone in prostate cancer (PCa), sponsored by N/A. Started Nov 2025; status: active, not recruiting.
02
Drugs
docetaxelabiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on TCTR20260530001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260530001.